CN104248757B - Porcine pseudorabies virus vaccine composition and preparation method and application thereof - Google Patents
Porcine pseudorabies virus vaccine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN104248757B CN104248757B CN201410519314.2A CN201410519314A CN104248757B CN 104248757 B CN104248757 B CN 104248757B CN 201410519314 A CN201410519314 A CN 201410519314A CN 104248757 B CN104248757 B CN 104248757B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- prv
- porcine pseudorabies
- pseudorabies virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 139
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 239000002671 adjuvant Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 235000019624 protein content Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 3
- 235000013601 eggs Nutrition 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 25
- 230000001900 immune effect Effects 0.000 abstract description 11
- 239000013598 vector Substances 0.000 abstract description 4
- 208000010359 Newcastle Disease Diseases 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 239000013612 plasmid Substances 0.000 description 34
- 241000282898 Sus scrofa Species 0.000 description 25
- 241000700605 Viruses Species 0.000 description 20
- 241000711404 Avian avulavirus 1 Species 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 239000000969 carrier Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000036760 body temperature Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 238000003306 harvesting Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 208000009305 pseudorabies Diseases 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 239000002574 poison Substances 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000021050 feed intake Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 101150036031 gD gene Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 206010020741 Hyperpyrexia Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000010726 hind limb paralysis Diseases 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 206010030899 opisthotonus Diseases 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 108010041963 Newcastle disease virus nucleoprotein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010036600 Premature labour Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 101150029683 gB gene Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000005571 horizontal transmission Effects 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 208000026440 premature labor Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000010572 single replacement reaction Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a porcine pseudorabies virus vaccine composition, which contains a porcine pseudorabies virus subunit antigen or a recombinant newcastle disease virus-porcine pseudorabies virus vector. The invention also provides a preparation method and application of the vaccine composition. The vaccine composition can effectively prevent diseases related to the porcine pseudorabies virus and diseases related to infection caused by the porcine pseudorabies virus. The combination of the immunogenic antigens in the porcine pseudorabies virus vaccine composition can induce the generation of a synergistic immune effect, so that the immune effect is good, the immune usage amount is further reduced, and the immune cost is reduced.
Description
Technical field
The invention belongs to veterinary biologics field, vaccine combination and its preparation more particularly to PRV
Method, and the immunizing antigen is used to prepare prevention and/or treated with PRV relevant disease and mad by pig puppet
The application of the composition of infection caused by dog disease poison.
Background technology
Pseudoabies, also known as AujeszkyShi disease, are by the pig blister in herpetoviridae (Herpesviridae) α subfamilies
A variety of domestic animals, poultry and the wild animals such as pig, ox, sheep caused by the type of exanthema virus I (Suid herpesvirus 1strain)
It is a kind of to generate heat, very itch (in addition to pig) and encephalomyelitis as primary symptom acute infectious disease.The pseudoabies of pig is extensive in China
In the presence of harm is serious, is to restrict one of main epidemic disease of large-scale pig farm production.It can cause in-pig miscarriage, stillborn foetus or
There is nervous symptoms, paralysis in mummy tire and piglet, and the death rate is high.PRV has stronger pantropic, neurotropism and latent sense
Contaminate characteristic, peripheral neverous system can latent infection for a long time, become infectious virus when latent virus is activated, dived
The host of volt infection will fall ill.
Pig PRV only one of which serotypes, it is generally recognized that the cross-protection of strain is very strong, but still suffers from piggy injection at present
Typical porcine pseudorabies occur after commercialized vaccine, such as long-time body temperature is raised, spiritual depressed, anorexia is breathed
Road and/or nervous symptoms.Outstanding behaviours can all be infected for the pig at any age, can be in swinery horizontal transmission, and incubation period is short by (1~2
My god), the incidence of disease is between 10%~100%, and (the piglet death rate may be up to the morbid pig death rate between 10%~100%
100%) pig hyperpyrexia (40~42 DEG C, continue more than 3 days), can be caused after infection, had difficulty in breathing, diarrhoea is breathed heavily, and is coughed, is played spray
Sneeze, hindlimb paralysis, dog sits, and falls down to the ground suddenly, twitch, can not lie on one's side, opisthotonos, swimming shape is struck, and is finally died of exhaustion, and can draw
Play herd boar semen quality to decline, farrowing sow miscarriage (up to 35%), premature labor, stillborn foetus is weak young (all dead before weak young 14 age in days
Die) etc. breeding difficulty symptom.It can not be attacked after the vaccine immunity pig of prior art fully against wild poison, height still occurs
Heat, spirit is depressed, loss of appetite or the useless symptom such as absolutely, infection rate more than 80%, the incidence of disease more than 30%, the death rate 10%~
Between 20%.The also no vaccine of prior art can solve the problem that for pseudoabies caused by pseudorabies variant.
First passage of the present invention uses PRV gB albumen with gD protein combinations, for pseudorabies variant
Caused pseudoabies has preferable protective effect, by immune efficacy comparative test, have been surprisingly found that, two kinds of protein combinations
Use, collaboration stimulates organism immune response, effectively reduces immunizing dose, greatly reduces immune cost.
The content of the invention
It is an object of the invention to overcome prior art defect, there is provided one kind prevention and/or treatment PRV sense
The vaccine combination of dye, the vaccine combination includes two kinds of PRV immune protective antigens and adjuvant.The present invention is carried
Two kinds of PRV immunizing antigens that the vaccine combination of the prevention of confession and/or treatment PRV infection is included are
GB albumen and gD albumen.
The first aspect of the present invention is a kind of porcine pseudorabies virus vaccine combination, and described vaccine combination includes exempting from
GB albumen, gD albumen and the adjuvant of epidemic disease amount.
It is used as a kind of preferred embodiment of the present invention, in the vaccine combination of the present invention, described gB proteins
Sequence is SEQ ID NO.3；Described gD proteins sequence is SEQ ID NO.4.
Preferably, the prevention that the present invention is provided and/or the pig that the vaccine combination for the treatment of PRV infection is included
Pseudorabies virus immunizing antigen gB protein amino acid sequences such as SEQ ID NO：Shown in 3.
Preferably, the prevention that the present invention is provided and/or the pig that the vaccine combination for the treatment of PRV infection is included
Pseudorabies virus immunizing antigen gB protein nucleotide sequences such as SEQ ID NO：Shown in 1.
Preferably, the prevention that the present invention is provided and/or the pig that the vaccine combination for the treatment of PRV infection is included
Pseudorabies virus immunizing antigen gD protein amino acid sequences such as SEQ ID NO：Shown in 4.
Preferably, the prevention that the present invention is provided and/or the pig that the vaccine combination for the treatment of PRV infection is included
Pseudorabies virus immunizing antigen gD protein nucleotide sequences such as SEQ ID NO：Shown in 2.
Term " gB albumen " is also known as " gB glycoprotein ",
Term " gD albumen " is also known as " gD glycoprotein ", is that porcine pseudorabies virus carries out infecting required structural proteins, is
One of ripe primary glycoproteins on virion cyst membrane surface, also referred to as " gp50 albumen ".
The prevention that the present invention is provided and/or the porcine pseudorabies that the vaccine combination for the treatment of PRV infection is included
Malicious immunizing antigen gB albumen, gD albumen can also be the polypeptide of the amino acid sequence essentially identical with its functional derivative.
Term " adjuvant ", which refers to, to be added in the composition of the present invention with the material for the immunogenicity for increasing composition.It is known
Adjuvant includes, but are not limited to：Oily adjuvant, water-soluble adjuvant, Alum adjuvant, Cytokine adjuvant.
Term used herein " oily adjuvant " is also known as " oil adjuvant " or " oil emulsion adjuvant ", is by including vegetable oil, animal
One or more of compositions in oil, mineral oil, for delaying RT of the immunogene in body, are allowed to continue slowly to release
Put, strengthen phagocytosis and the sterilizing ability of macrophage.
Term used herein " water-soluble adjuvant " is also known as " water-based adjuvant " or " water adjuvant ", is a kind of polymeric water-soluble
Dispersion, effect and security for improving water-soluble vaccines can be by high molecular weight polypropylene acids synthetic polymer groups
Into.
Term used herein " Alum adjuvant ", also known as " aluminium glue adjuvant " or " aluminium adjuvant ", including aluminum hydroxide adjuvant and
Aluminium phosphate adjuvant, its major function is sustained release, but has the activation to immunocyte simultaneously.By antigen and aluminium hydroxide or
Aluminum phosphate hybrid injection, can make antigen be stored in injection site, with antigen sustained release and nonspecific immunity stimulation.
Term used herein " Cytokine adjuvant ", including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-10, IL-12, IL-15, IL-18, INF- γ, GM-CSF, TNF-α, TNF-β, TCA-3 etc., also known as " cell factor " or " thin
Born of the same parents' element ", is that the secretion of live body host cell by diffusion, cell contact or blood circulation reaches other cells of host, in body
A class non-immunoglobulin, local native protein or the glycoprotein played a role in liquid with extremely low concentration is also a class by body
The immunocyte of activation and some nonimmune cells are produced, secretion, can adjust cell growth, differentiation, with hematopoiesis, inflammatory reaction,
The general designation of the closely related high activity multi-functional small molecules albumen such as immune response and wound healing, can stimulate or suppress
Immunologic function, promotes cell development differentiation, regulation cell physiological function and cell-tocell transmission, immune in immune response
Very important regulating and controlling effect is played in system.
A kind of 206 adjuvant in oily adjuvant has been used in the embodiment of the present invention.
Amount suitable for the adjuvant of the composition of the present invention is preferably effective dose." effective dose " refers to adjuvant same
Played in host during antigen combined administration of the invention for their immunological role must or it is enough excessive without causing
Side effect institute necessary amounts.The accurate amount of adjuvant to be administered is by the class according to factor such as composition used and the disease for the treatment of
Type, the type of animal to be treated and age, the mode of administration, and other compositions in composition and change.
In one embodiment, the present invention provides a kind of vaccine group treated and/or prevent PRV infection
Compound, is made up of PRV immunizing antigen gB albumen, gD albumen and 206 adjuvants.
It is used as a kind of preferred embodiment of the present invention, in the vaccine combination of the present invention, described gB protein contents
For 25-100 μ g/ml；GD protein contents are 25-100 μ g/ml.
As a kind of most preferred embodiment of the present invention, in the vaccine combination of the present invention, described gB albumen contains
Measure as 50 μ g/ml；GD protein contents are 50 μ g/ml.
The composition of composition or the amount of component of the present invention is preferably therapeutically effective amount.The therapeutically effective amount refers to
Their immunological role is played without causing excessive side effect institute necessary amounts in the host that composition is applied.Composition used and
The accurate amount of composition to be administered is by according to factor such as the type of disease treated, the type of animal to be treated and year
Age, the mode of administration, and other compositions in composition and change.
For animal pig, vaccine combination gB proteantigens effective dose of the present invention is 25-100 μ g/ml；
GD proteantigens effective dose is 25-100 μ g/ml.
It is highly preferred that the vaccine combination gB proteantigens effective dose is 50 μ g/ml；GD proteantigens effective dose is 50
μg/ml。
Another aspect of the present invention is a kind of porcine pseudorabies virus vaccine combination, and described vaccine combination includes weight
Group NDV-porcine pseudorabies virus carrier and adjuvant.
It is used as a kind of preferred embodiment of the present invention, in the vaccine combination of the present invention, described recombinant Newcastle disease
Virus-porcine pseudorabies virus carrier includes one or more heterologous polynucleotides, and it encodes one or more porcine pseudorabies
Viral antigen, polypeptide or its variant, wherein, described porcine pseudorabies virus antigen includes gB albumen, gD albumen.
Term " functional derivative " refers to the functional biological work substantially similar with the bioactivity of intact proteins/peptide sequence
Albumen/peptide sequence of property.In other words, it refers preferably to, when the functional derivative is applied into animal, substantially remain
Immune response is excited, the polypeptide or its fragment of the ability for the aversion response such as attacked for porcine pseudorabies strain.
Term " fragment " refers to such polynucleotide sequence, its be artificial constructed (such as by chemical synthesis) or by will
Natural products is cracked into the separation of the nucleic acid of the present invention of multiple small fragments (using restriction enzyme, or mechanical shearing) structure
Part, or the nucleic acid synthesized by PCR, archaeal dna polymerase or any other polymerization technique well known in the art part, or pass through
Well known to a person skilled in the art the nucleic acid moiety that recombinant nucleic acid technology is expressed in host cell.
As being commonly understood by and using herein, " functional fragment " refers to the basic phase of bioactivity of coding and complete nucleic-acid sequences
As functional biological activity nucleotide sequence.In other words, in the context of the present invention, it refers preferably to substantially remain volume
The nucleic acid or its fragment of the such polypeptides/proteins ability of code, the polypeptides/proteins are excited and are directed to when being applied to animal
The immune response of PRV attack, and more preferably aversion response.
When referring to amino acid sequence, the polypeptide that " substantially the same " can be understood as the present invention preferably has such ammonia
Base acid sequence, itself and SEQ ID NO：The part or all of of sequence shown in 3-4 has at least 70% homology, or even excellent
The homology of selection of land 80%, or even more preferably still 90% homology, or most preferably 95% homology.
Term " homology " herein is also including same or like with reference sequence, while providing the letter of any amino acid
Single replacement/modification.BLAST-P (basic part parallelism gopher) can be used, well known to a person skilled in the art program progress
The homology search of this aspect.For corresponding nucleotide sequence, homology be related to the BLASTX that is known in the art and
BLASTN programs.
It is used as a kind of preferred embodiment of the present invention, in the vaccine combination of the present invention, described porcine pseudorabies
Viral antigen gB albumen is the porcine pseudorabies virus gB albumen that sequence SEQ ID NO.3 are encoded, the porcine pseudorabies virus stated
Antigen gD albumen is the gD albumen that sequence SEQ ID NO.4 are encoded.
" carrier " means recombinant DNA or RNA plasmids, bacteriophage or virus, and it includes and delivered in vivo or in vitro
To the heterologous polynucleotide of target cell.The purpose that heterologous polynucleotide can prevent or treat comprising aim sequence, it is optional
Ground, it is the form of expression cassette.Carrier be able to need not be replicated in final target cell or subject.Term " carrier " includes
For cloning vector, also including viral vector.
As a kind of preferred embodiment of the present invention, the vaccine combination described in the vaccine combination of the present invention,
Characterized in that, described NDV is low virulent strain, it is preferable that institute's NDV is Sota plants of NDV La.
Sota plants of NDV La is purchased from China Veterinery Drug Inspection Office.
Another aspect of the present invention is a kind of method for preparing the vaccine combination, and described method includes：1) prepare
The step of gB albumen and gD proteantigens；And 2) hybrid antigen in proportion, add the step of adjuvant, emulsification.
Treated and/or prevention PRV relevant disease or infection it is a further object to provide a kind of
The preparation method of vaccine combination, including：
(1) gB albumen and gD proteantigens are prepared；
(2) hybrid antigen in proportion, adds adjuvant, emulsification.
The preparation of antigen can be carried out by a variety of methods well known by persons skilled in the art, including genetic engineering means,
For example pass through the clone comprising polynucleotides of the present invention or expression vector.Term " carrier ", which is related to, is designed to transduction/transfection
The polynucleotide constructs of one or more cell types.Carrier can be, such as " cloning vector ", and it is designed to point
From, propagation and replicate insertion nucleotides；" expression vector ", it is designed in host cell express nucleotide sequence；
Or " viral vector ", it is designed to production recombinant virus or virus-like particle；Or " shuttle vector ", it includes more than one
The property of the carrier of type.Being adapted to prepare the publicly available carrier of PRV antigen of the present invention includes plasmid, gland
Virus, baculoviral, yeast baculoviral, plant virus, adeno-associated virus, retroviruse, herpes simplex virus, α virus,
Slow virus etc., can also obtain the method for building such carrier.The preparation of PRV antigen of the present invention also includes logical
Artificial synthesized mode is crossed to realize.
Another aspect of the present invention is a kind of method for preparing the vaccine combination, it is characterised in that described method
Including：1) the step of recombinating the newcastle disease virus gene group full-length cDNA carrier；2) recombinantly express the Newcastle disease virus NP,
The step of P, L expression vector；3) the porcine pseudorabies virus antigen gene is recombinantly expressed to the NDV base
The step of because of group full-length cDNA recombinant vector；And 4) by the NDV of the expression porcine pseudorabies virus antigen
Genomic full_length cDNA recombinant vector and the expression Newcastle disease virus NP, the common transfectional cell of P, L gene recombined vector, are carried out
Virus is shaken the step of rescuing.
It is used as a kind of preferred embodiment of the present invention, in the vaccine combination preparation method of the present invention, transfectional cell
For bhk cell.Also other cell line cells well known in the art for cultivating NDV be can select.
Another aspect of the present invention is that described vaccine combination is preparing prevention and/or treatment porcine pseudorabies virus phase
Related disorders or by the application in the medicine infected caused by porcine pseudorabies virus.
It is another object of the present invention to provide include PRV immunizing antigen gB albumen, gD albumen or its work(
The polypeptide of the essentially identical amino acid sequence of energy derivative is for preventing and/or treating PRV relevant disease or sense
Application in the composition and/or method of dye.
Term " prevention ", which refers to, to be suppressed pseudorabies infection by the vaccine combination given according to the present invention or postpones disease
All behaviors of breaking-out.Term " treatment " refers to infects porcine pseudorabies virus by giving according to the vaccine combination of the present invention
Caused symptom mitigation or all behaviors taken a turn for the better.
Term " aversion response " is meant prevents PRV relevant disease or by PRV in animal
The breaking-out of caused infection or the seriousness for mitigating the such disease existed.
PRV polypeptide of the present invention, it advantageously excites the aversion response in animal.Specifically, originally
Invent the polypeptide being related to and include the amino acid sequence essentially identical with its functional derivative.
Treatment and/or prevention PRV are being prepared it is a further object to provide a kind of vaccine combination
The application of relevant disease or the medicine of infection.
Term " porcine pseudorabies virus relevant disease " used herein is used to refer to caused by PRV infection
Disease.Its example include morbidity piglet show obvious nervous symptoms, lethargic sleep, toot cry, vomit, having loose bowels, body temperature rise, one
Denier is fallen ill, and farrowing sow can miscarry, produce mummy fetus or stillborn foetus or breeding difficulty, but not limited to this.
Term " porcine pseudorabies virus relevant disease " used herein can be further used for finger and show as any age
Pig can all infect, can be in swinery horizontal transmission, incubation period is short (1~2 day), and the incidence of disease is between 10%~100%, morbid pig
The death rate (the piglet death rate may be up to 100%) between 10%~100%, can cause after infection pig hyperpyrexia (40~42 DEG C,
Continue more than 3 days), have difficulty in breathing, diarrhoea is breathed heavily, and is coughed, is sneezed, and hindlimb paralysis, dog sits, and falls down to the ground suddenly, is twitched, is lain on one's side not
Rise, opisthotonos, swimming shape is struck, and is finally died of exhaustion, and herd boar semen quality can be caused to decline, farrowing sow miscarriage is (high
Up to 35%), premature labor, stillborn foetus, the breeding difficulty symptom such as weak young (all dead before weak young 14 age in days), but not limited to this.Above-mentioned disease
The symptom difference that shape is produced with having infected in the prior art after common porcine pseudorabies virus is：Infection can be caused after having infected
Adult Pig (body weight is in more than 50kg pigs) can cause pig hyperpyrexia (40~42 DEG C, continue more than 3 days) afterwards, have difficulty in breathing, diarrhoea,
Breathe heavily, cough, sneeze, hindlimb paralysis, dog sits, and falls down to the ground suddenly, twitch, can not lie on one's side, opisthotonos, swimming shape is struck, and is finally declined
Exhaust and dead；Piglet sudden onset within newborn and 4 week old, occurs large quantities of death, and the death rate is up to more than 90%；Fall ill piglet master
Show as body temperature to rise up to more than 41 DEG C, appetite is useless exhausted, with obvious nervous symptoms and diarrhoea；Pre-and Post-Weaning Piglets are main
For Respiratory symptoms, performance expiratory dyspnea, cough, rhinorrhea etc..
The present invention has the advantages that following prominent：
(1) vaccine combination of the present invention can pass through the component of genetic engineering means or artificial synthesized means to vaccine combination
A large amount of synthesis expression are carried out, it is not only time-consuming short, it can also be easy to large-scale production；
(2) combination of many immunogenic antigens can induce and produce collaboration in PRV vaccine combination of the present invention
Immune effect, not only immune effect is good, further reduces immune usage amount, reduces immune cost；
(3) infection that vaccine combination of the present invention can effectively protect pig to resist PRV is finished there is provided one
The approach of kind prevention and/or treatment PRV infection, it is to avoid traditional live vaccine virulence returns the hair of strong and scattered malicious risk
It is raw, there is positive realistic meaning for purification PRV.
Brief description of the drawings
Fig. 1 is gB gene PCR amplified production electrophoresis results, and each swimming lane is respectively from left to right：Marker DL5000、gB
Gene PCR amplified production, extracting negative control pcr amplification product, PCR negative controls；
Fig. 2 is gD gene PCR amplified production electrophoresis results, and each swimming lane is respectively from left to right：Marker DL5000, take out
Carry negative control pcr amplification product；3：PCR negative controls；4：GD gene PCR amplified productions；
Fig. 3 is pFastBac/HBM-TOPO-gB digestion qualification results, and each swimming lane is respectively from left to right：Marker
DL5000；2-5 swimming lanes：PFastBac/HBM-TOPO-gB Mlu I and the digestion qualification results of Hind III；
Fig. 4 is pFastBac/HBM-TOPO-gD digestion qualification results, and each swimming lane is respectively from left to right：Marker
DL5000；2-4 swimming lanes：PFastBac/HBM-TOPO-gD Mlu I and the digestion qualification results of Hind III；
Fig. 5 is Bacmid-gB and Bacmid-gD PCR qualification results, and each swimming lane is respectively from left to right：Marker
DL5000, Bacmid-gB PCR identifications, Bacmid-gD PCR identifications, Bacmid PCR negative controls；
Fig. 6 is that vNDV-PRV-gB-gD builds schematic diagram.
In sequence table：
Sequence 1 is the nucleotide sequence of HN1201 plants of gB albumen of PRV；
Sequence 2 is the nucleotide sequence of HN1201 plants of gD albumen of PRV；
Sequence 3 is the amino acid sequence of HN1201 plants of gB albumen of PRV；
Sequence 4 is the amino acid sequence of HN1201 plants of gD albumen of PRV.
Embodiment
The invention will now be further described with reference to specific embodiments, and advantages of the present invention and feature will be with description more
To be clear.But these embodiments are only exemplary, do not constitute any limitation to the scope of the present invention.Those skilled in the art
It should be understood that can be carried out without departing from the spirit and scope of the invention to the details and form of technical solution of the present invention
Modifications or substitutions, but these are changed and replacement is each fallen within protection scope of the present invention.
The preparation of PRV gB, gD albumen of embodiment 1
1. the amplification of PRV gB, gD gene
PRV HN1201 viruses or the culture of its different generation, the different generations are inoculated with well-grown PK15 cells
Secondary culture is the culture within 5-35 generations, and TAKARA companies MiniBEST Viral RNA/DNA are used after harvest is viral
Extraction Kit Ver.3.0 kits extract PRV genomic DNAs.Take 1 μ l genomic DNAs template, be utilized respectively
GB, gD specific primer：
gBSF:5 ' CTAGGGGGCGTCGGGGTCCTCGT 3 ' and
gBSR:5′ATGCCCGCTGGTGGCGGTCTTTGG3′
gDSF:5 ' ATGCTGCTCGCAGCGCTATTGGC 3 ' and
gDSR:5′CTACGGACCGGGCTGCGCTTTTAG3′
Enter performing PCR amplification, utilize TAKARA high-fidelity enzyme HS DNA Polymerase with
GC Buffer, gB amplification conditions are：94℃3min；98 DEG C of 10s, 68 DEG C of 3min, 30cycles；68 DEG C of 5min, PCR primer life
Entitled gB.GD amplification conditions are：94℃3min；98 DEG C of 10s, 68 DEG C of 1min, 30cycles；68℃5min.PCR primer is named as
gD。
2. recombinate Bacmid acquisition and identification
The PCR primer gB and gD that high-fidelity enzymatic amplification is obtained are cloned into pFastBac/HBM-TOPO carriers and (are purchased from respectively
Invitrogen companies, article No. A11339), clone's system is as follows：PCR primer gB 4 μ l, Salt solution (salting liquid) 1 μ
L, TOPO vector1 μ l, totally 6 μ l.It is well mixed, it is incubated at room temperature 5min, conversion One ShotR Mach1TMT1R competence is thin
Born of the same parents, are coated with amicillin resistance flat board, and picking monoclonal identifies the direction of insertion of gB, gD gene respectively, and direction of insertion is correct
Plasmid send Invitrogen companies be sequenced, identify gB, gD sequence correctness.Correct plasmid is sequenced to be respectively designated as
PFastBac/HBM-TOPO-gB, pFastBac/HBM-TOPO-gD.
PFastBac/HBM-TOPO-gB, pFastBac/HBM-TOPO-gD plasmid are converted into DH10Bac competence respectively
Cell, pFastBac/HBM-TOPO-gB, pFastBac/HBM-TOPO-gD respectively with the shuttle plasmid in competent cell
Bacmid carries out swivel base, is extracted and obtained with Invitrogen PureLink HiPure Plasmid DNA Miniprep Kit
Recombinant plasmid, and identify with pUCM13Forward/pUCM13Reverse primers gB, gD insertion, positive Bacmid respectively
It is respectively designated as Bacmid-gB, Bacmid-gD.
3. transfection obtains recombinant baculovirus
According to saying for Invitrogen companies Bac-to-Bac HBM TOPO Secreted Expression System
The method that bright book is provided is carried out.6 orifice plates paving 8 × 10 per hole5Individual sf9 cells, after after cell attachment according to II turn of Cellfectin
The specification of transfection reagent is transfected：8 μ l Cellfectin II and 1 μ g Bacmid-gB DNA to 100 μ l are diluted respectively
In the culture mediums of SF-900 II, Vortex is mixed, the DNA after mixed diluting and the Cellfectin II after dilution (cumulative volume~
210 μ l), it is well mixed and is incubated at room temperature 15~30min, it is one after another drop of to be added in cell.After transfection after 72h cytopathies to appear,
Cells and supernatant is collected, P0 is designated as recombinant virus vBac-gB.P0 infects sf9 cells for recombinant virus vBac-gB, through 3 generations
Expand after culture, the P3 of acquisition is used for expression of recombinant proteins for vBac-gB.
Above-mentioned transfection method is equally pressed, Bacmid-gD DNA are transfected, the recombinant virus of harvest is designated as P0 generations
vBac-gD.P0 infects sf9 cells for recombinant virus vBac-gD, and after expanding culture through 3 generations, the P3 of acquisition is used for for vBac-gD
Expression of recombinant proteins.
4. recombinate shape virus infection High-five cells obtain recombinant protein
P3 (is purchased from for recombinant baculovirus vBac-gB, vBac-gD inoculation High-five cells respectively
Invitrogen, article No. B85502).Suspended culture High-five cells in 500ml triangular flasks, and 7.0 are reached to cell density
×105After cell/ml, according to 1MOI amount virus inoculation, 72h collects cells and supernatant after infection.Utilize Millipore's
Volume concentration is the 1/10 of original volume by tangential flow filtration system.(it is purchased from the Triton X-100 of 1% (volume ratio)
Sigma, article No. T8787) inactivation baculoviral, it is 200 μ g/ml that SDS-PAGE optical densitometric methods, which determine protein content,.
Implement the preparation of 2 PRV vaccine combinations
Example 1 prepare gB and gD albumen, be added slowly in adjuvant, plus during be constantly with rotating speed
800rpm mulsers stir 12min, mix, 4 DEG C of preservations, the as vaccine combination of PRV.Specific proportioning is shown in Table
1。
The PRV vaccine combination composition proportion of table 1
The Study On Immunogenicity of the PRV vaccine combination of embodiment 3
21 age in days PRV negative antibodies piglets 36 are randomly divided into 9 groups, 4/group, i.e. 1-7 groups are respectively that the present invention is implemented
The vaccine 1 of the preparation of example 1, vaccine 2, vaccine 3, vaccine 4, vaccine 5, vaccine 6, the immune group of vaccine 7, the 8th group and the 9th group of injection equivalent
PBS, single immunization.Poison is attacked after 28 days after immune, toxic agent amount is attacked for porcine pseudorabies virus HN1201 strains 2 × 108.0TCID50/
Head, the daily set time observes clinical condition and measures body temperature in 7 days after attack.
As a result in the case where this attacks toxic agent amount, 4 piglets of 1-7 immune groups are protected, and of short duration clinical sign occur at 5 days
Progressively recover normal, final survival afterwards；8th group of 2 days dead 2 after poison is attacked, 3 days all dead, there is obvious clinical sign；The
9 groups of survivals, phenomenon without exception occurs.Attack poison protection and the results are shown in Table 2.
The porcine pseudorabies virus vaccine combination of table 2 is immunized after piglet and attacks poison protection result
Judge for animal, the clinical sign for assessing disease is carried out in the case of all individual immunities are not known
, body temperature rising condition is shown in Table 3.Clinical pig body temperature rise number of days statistics, vaccine is compared using ANOVA analyses to piglet body
The effect of temperature change.As a result body temperature rise difference not significantly (P ＞ are shown between vaccine 1, vaccine 2, vaccine 3 and the immune group of vaccine 4
0.05), difference is not notable (P ＞ 0.05) between vaccine 5, vaccine 6 and the immune group of vaccine 7, and vaccine 1, vaccine 2, vaccine 3, epidemic disease
Seedling 4 is extremely notable (P ＜ 0.01) with difference between vaccine 5, vaccine 6, vaccine 7.Number of days is raised by relative immunity piglet body temperature to put down
Average, as a result shows that the body temperature rise number of days average value and vaccine 1, vaccine 2, vaccine of piglet is immunized in vaccine 5, vaccine 6 and vaccine 7
The 3 body temperature rise number of days average values that piglet is immunized with vaccine 4 are compared to be dropped to 1-1.25 days by 2.75-3 days, averagely have dropped
54.5%-66.7%.Pass through the clinical evaluation result correlation of the immune efficacy of relatively more each vaccine, it can be seen that vaccine 5, vaccine 6
To be significantly higher than vaccine 1, vaccine 2, vaccine 3 and vaccine 4 with the immune effect of vaccine 7.Demonstrate the present invention and include two kinds of antigens
Vaccine combination immune effect is better than single antigen vaccine, and also found, the present invention includes two kinds of antigenc vaccine compositions
With lower antigenic content, more preferable immune effect can be but reached, by comparing influence of the vaccine to clinical disease, this hair
Bright vaccine combination clinical disease is considerably less than single antigen vaccine.
The body temperature rising condition after piglet is immunized in the porcine pseudorabies virus vaccine combination of table 3
| Group | A (my god) | B (my god) | C (my god) | D (my god) | Average value (my god) |
| 1 | 3 | 3 | 3 | 3 | 3 |
| 2 | 3 | 3 | 3 | 2 | 2.75 |
| 3 | 3 | 2 | 3 | 3 | 2.75 |
| 4 | 2 | 3 | 3 | 3 | 2.75 |
| 5 | 1 | 1 | 1 | 2 | 1.25 |
| 6 | 1 | 1 | 1 | 1 | 1 |
| 7 | 1 | 1 | 1 | 1 | 1 |
| 9 | 0 | 0 | 0 | 0 | 0 |
Further each test group piglet feeding situation is counted, 4 are the results are shown in Table.7 days feed intake statistics of clinical pig,
Compare the effect that vaccine changes to piglet feed intake using ANOVA analyses.As a result vaccine 1, vaccine 2, vaccine 3 and vaccine are shown
Feed intake difference is not notable (P ＞ 0.05) between 4 immune groups, the not notable (P of difference between vaccine 5, vaccine 6 and the immune group of vaccine 7
＞ 0.05), and vaccine 1, vaccine 2, vaccine 3, vaccine 4 are extremely notable (P ＜ 0.01) with difference between vaccine 5, vaccine 6, vaccine 7.
By relative immunity piglet feed intake average value, as a result show that the feed intake average value of piglet is immunized in vaccine 5, vaccine 6 and vaccine 7
Risen to compared with the feed intake average value that piglet is immunized in vaccine 1, vaccine 2, vaccine 3 and vaccine 4 by 210.89g-215.21g
285.56g-290.57g, averagely rise 37.78%-32.69%.Knot is judged by the immune efficacy clinic of relatively more each vaccine
Fruit correlation, it can be seen that the immune effect of vaccine 5, vaccine 6 and vaccine 7 will be significantly higher than vaccine 1, vaccine 2, vaccine 3 and epidemic disease
Seedling 4.Further demonstrate the present invention and be better than single antigen vaccine comprising two kinds of antigenc vaccine compositions immune effects.
Situation of searching for food is immunized after piglet in the porcine pseudorabies virus vaccine combination of table 4
| Group | A(g) | B(g) | C(g) | D(g) | Average value (g) |
| 1 | 215.90 | 210.14 | 208.00 | 209.54 | 210.89 |
| 2 | 214.50 | 210.24 | 210.08 | 211.42 | 211.56 |
| 3 | 210.08 | 211.80 | 219.60 | 209.12 | 212.64 |
| 4 | 220.74 | 214.63 | 216.14 | 209.35 | 215.21 |
| 5 | 280.42 | 275.26 | 298.34 | 288.24 | 285.56 |
| 6 | 295.21 | 289.28 | 287.35 | 290.45 | 290.57 |
| 7 | 291.14 | 288.84 | 292.08 | 287.42 | 289.87 |
| 9 | 288.45 | 290.54 | 287.96 | 296.35 | 290.83 |
The preparation of porcine pseudorabies virus vaccine of the embodiment 4 using NDV as carrier
1. the structure of Sota plants of total length carriers of NDV La
(1) NDV propagation and RNA are extracted, RT-PCR
By Newcastle Disease Virus Vaccine with based on Sota plants of low virulent strain La, learned with reference to Hua Zhong Agriculture University master in 2012
Structure and the identification of degree thesis whole-length NDV La Sota pnca genes group full-length cDNA carriers and NP, P helper plasmid, take NDV La Sota
Strain virus uses the Trizol Reagent (article No.s of Invitrogen companies in the culture of SPF chicken embryos after harvest is viral：
NDV RNA 12183-555) are extracted, with the Reverse Transcriptase M-MLV (article No.s of TAKARA companies：2641A) try
Agent box prepares cDNA.
(2) structure of NDV La Sota plants of each fragment
The NDV LaSota pnca gene groups sequence (gene order number is AF077761) announced with reference to Gene Bank, uses NEB
Cutter softwares are to the restriction endonuclease analysis of NDV La Sota pnca gene groups, with reference to the multiple cloning sites of pBR322 carriers,
It is divided into 8 fragment amplification full length viral genomes, FseI and PacI enzymes is introduced respectively in the downstream of M genes and the upstream of F genes
Enzyme site, and ' end adds T7 polymerase promoters, in its 3 ' Hepatitis D virus core that introducing self can be modified behind end 5
Enzyme core sequence (HdvRz), 8 pairs of primers of design are expanded (primer see the table below).With the high-fidelity enzyme of TAKARA companiesHS DNA Polymerase, PCR expand NDV each fragment gene, and PRC conditions are：94℃2min；
98 DEG C of 10s, 55 DEG C of 15s, 72 DEG C of 1min/kb (extension of time is adjusted according to each fragment length), 30cycles；72℃10min.
NDV1-UP:5′
CGGCgaattcTAATACGACTCACTATAGGACCAAACAGAGAATCCGTGAG3′
NDV1-DOWN:5′CATgggcccTTTTTAGCATTGGAC3′
NDV2-UP:5′TGCTAAAAAgggcccATGGTCGAG3′
NDV2-DOWN:5′ATTCcacgtgCTTGACTGCATTCACTG3′
NDV3-UP:5′ATTCcacgtgCGTGAAAGCGCCAGAGAAGA 3′
NDV3-DOWN:5′
CAAAttaattaaGAACTAggccggccCTAACTTGATAGACAGGTAA3′
NDV4-UP:5′ATTCttaattaaAAAAAACACGGGTAGAAGAT3′
NDV4-DOWN:5′AGCTGcggccgcTGTTATTTGTGC 3′
NDV5-UP:5′AACAgcggccgcAGCTCTGATACAAGC3′
NDV5-DOWN:5′GATCcgtacgAATGCTGCTGAACTCCTC 3′
NDV6-UP:5′CATTcgtacgGATCCGGCATTCTGGTT 3′
NDV6-DOWN:5′GTTTcttaagAACAATATTTGGGCTTG 3′
NDV7-UP:5′TGTTcttaagAAACATACGCAAAGAGT 3′
NDV7-DOWN:5′
CGAGatttaaatACATGTAGTACAGATTAGCTGGGAATG 3′
NDV8-UP:5′ATGTatttaaatCTCGGAAGAGCCTCAATTTGATCA 3′
NDV8-DOWN:5′CCGGacgcgtACCAAACAAAGATTTGGTGAATG3′
(3) structure of NDV La Sota plants of total length carrier
According to the multiple cloning sites of NDV La Sota pnca gene group restriction endonuclease analysis and pBR322 carriers, synthesis
One section of 265bp sequence (including EcoR I, Apa I, Pml I, Fse I, Pac I, Not I, Bsiw I, Afl II, Swa I,
Mlu I and the restriction enzyme sites of Hind III multiple cloning sites sequence, and HdvRz and T7 terminator sequences：
GAATTCGGGCCCCACGTGGGCCGGCCTTAATTAAGCGGCCGCCGTACGCTTAAGATTTAAATACGCGTACGCGTGGG
TCGGCATGGCATCTCCACCTCCTCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGGCT
GCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTC
TAAACGGGTCTTGAGGGGTTTTTTGCTGAAGCTT, plasmid is named as pMD18T-HT.
By pMD18T-HT plasmids EcoR I and the digestions of Hind III, will containing multiple cloning sites sequence, HdvRz sequences and
The fragment of T7 terminator sequences is cloned into EcoR I and Hind III site of pBR322 carriers, and the positive plasmid of acquisition is named as
pBRT7H.NDV La Sota full-length genomes PCR is then expanded to the NDV1~8DNA fragments obtained according to the clone time shown in figure
Sequence, is attached using the overlapping restriction endonuclease sites of genome adjacent segment and is assembled into pBRT7H carriers, final to build
Plasmid be named as pBRT7H-La.The carrier of structure is sequenced simultaneously, it is ensured that base sequence it is correct.
2. structure and the identification of helper plasmid
, respectively will coding NDV NPs, phosphoprotein P and polymerase protein L genes ORF based on pCI-neo carriers
Multiple cloning sites of the cDNA clone under the T7 promoters of pCI-neo carriers, the plasmid of structure be respectively designated as pCI-NP,
PCI-P and pCI-L.
After the plasmid of structure largely extracting, harvesting sample after bhk cell, transfection 72h is transfected respectively, anti-new city is used
Epidemic disease standard serum is primary antibody, and the sheep anti-chicken IgG of horseradish peroxidase-labeled carries out WesternBlot identifications for secondary antibody；With anti-
Ewcastle disease standard positive serum is primary antibody, and the sheep anti-chicken IgG of FITC marks carries out indirect immunofluorescene assay for secondary antibody and shows structure
The helper plasmid built has expression.
3.NDV rescue and identification
The total length plasmid pT7H-La of structure and helper plasmid pCI-NP, pCI-P and pCI-L are used respectively
Lipofectamine 2000 is according to 4:2:2:1 ratio cotransfection bhk cell, after transfection cultivate 3~4d harvest nutrient solution and
Cell.The culture of harvest is inoculated with the passage of 9 age in days SPF chicken embryos, NDV HA detections, chick embryo allantois positive harvest HA is carried out
Liquid, the virus as saved.
By the virus infection bhk cell of rescue, the visible obvious green of Fluirescence observation is shown with indirect immunofluorescene assay
Fluorescence, it was demonstrated that the NDV pT7H-La plasmids of structure can be packaged into functional active virus under T7 promoters, also illustrate structure
Helper plasmid pCI-NP, pCI-P and the pCI-L built has functional activity.
4. build the NDV transcription plasmids containing PRV gB genes and gD genes
The amplification of PRV gB, gD genes
PRV HN1201 viruses or the culture (pseudorabies of its different generation are inoculated with well-grown PK15 cells
Sick Strain is HN1201 plants (Pseudorabies virus, strain HN1201), and preserving number is CCTCC NO.V
201311；It is preserved in China typical culture collection center；Preservation address is Wuhan, China Wuhan University, and preservation date is
On May 20th, 2013), the culture of the different generations is the culture within 5-35 generations, and TAKARA companies are used after harvest is viral
MiniBEST Viral RNA/DNA Extraction Kit Ver.3.0 kits extract PRV genomic DNAs.Take 1 μ l genes
DNA is as template for group, is utilized respectively gB, gD specific primer：
gBSF:5 ' GGGCTAGCCTAGGGGGCGTCGGGGTCCTCGT 3 ' and
gBSR:5′TTGAATTCATGCCCGCTGGTGGCGGTCTTTGG3′
gDSF:5 ' GGGCGGCCGCATGCTGCTCGCAGCGCTATTGGC 3 ' and
gDSR:5′TTTCTAGACTACGGACCGGGCTGCGCTTTTAG3′
Enter performing PCR amplification, utilize TAKARA high-fidelity enzyme HS DNA Polymerase with
GC Buffer, gB amplification conditions are：94℃3min；98 DEG C of 10s, 68 DEG C of 3min, 30cycles；68 DEG C of 5min, PCR primer life
Entitled gB.GD amplification conditions are：94℃3min；98 DEG C of 10s, 68 DEG C of 1min, 30cycles；68℃5min.PCR primer is named as
gD。
5 build the NDV transcription plasmids containing PRV gB genes and gD genes
By PRV gB genes (the SEQ ID NO of amplification:1) with pVAX1 carriers after Nhe I and the digestions of EcoR I, connection
PVAX1-gB plasmids are built, by pVAX1-gB plasmids and gD genes (SEQ ID NO:2) after Not I and the digestions of Xba I, connection
PVaX1-gB-gD plasmids are built, the pVAX1-gB-gD plasmids using structure is templates, and the method expanded by PCR obtains two ends and is
Pac I and the restriction enzyme sites of Fse I, and the insertion box containing T7 promoters, terminator.Primer is as follows：
gBDF:5 ' CATGGCCGGCCTAATACGACTCACTATAGGGAGAC3 ' and gBDR：5′
GCTCTTAATTAAAGCCATAGAGCCCACCGCATCCC3′
With Pac I and Fse I digestion PCR primers, clip size is about 4343bp.With Pac I and the digested plasmids of Fse I
PBRT7H-La, the fragment that generation size is 19812bp.By the two fragments connection generation plasmid pBRT7H-LP.
The generation and identification of the NDV carriers of 6 expression PRV gB and gD genes
For generation expression PRV gB genes and the engineered NDV carriers of gD genes, following reactant and bar have been used
Part.The plasmid pBRT7H-LP of step 3 is used as transcription plasmid.By plasmid pCI-NP, pCI-P and pCI-L be used separately as NP, P and
L protein expression plasmids.By these four plasmids, together cotransfection enters bhk cell.After 72 hours, bhk cell supernatant is connect
9 age in days SPF chicken embryos are planted with amplicon virus.After 3 days, harvest allantoic fluid and check hemagglutination activity using chicken red blood cells
(HA).It has successfully been obtained NDV-PRV-gB-gD infectious particles.Use QuiaAMP viral RNAs extracts kit (Qiagen)
Extract RNA.RT-PCR is carried out using one-step RT-PCR kit (Qiagen).Sequencing result show gB genes and gD genes with gram
It is grand enter to transcribe the gB genes and gD gene original series of plasmid be 100% identical.The recombinant viral vector is designated as vNDV-
PRV-gB-gD。
Clinical assessment of 7 pairs of NDV-PRV vaccines in pig
The vNDV-PRV-gB-gD vaccine immunity piglet situations of table 5
| Group | Immunization wayses | Immunizing dose | Piglet number | Attack toxic agent amount |
| vNDV-PRV-gB-gD | Subcutaneous inoculation | 2mL | 4 | 2×108.0TCID50 |
| PBS | Subcutaneous inoculation | 2mLPBS | 4 | 2×108.0TCID50 |
| Blank control | — | — | 4 | — |
21 age in days PRV negative antibodies piglets 20 are randomly divided into 3 groups, 4/group, vNDV-PRV-gB-gD are diluted to
107.0EID50/ mL, vNDV-PRV-gB-gD vaccine 2ml/ heads, control group inoculation PBS liquid 2ml/ heads are immunized according to table 5.After immune
Poison is attacked after 28 days, it is HN1201 plants of porcine pseudorabies virus 2 × 10 to attack toxic agent amount8.0TCID50/ head, observation clinical symptoms and death
Situation (the results are shown in Table 6).
Malicious situation is attacked after the vNDV-PRV-gB-gD vaccine immunity piglets of table 6
Table 6 is shown, after vNDV-PRV-gB-gD vaccine immunity piglets, although is unable to blocking virus infection and (clinical condition occurs
Shape), but 100% (4/4) protection can be provided for piglet, and compare piglet and attack all dead after 4 days after poison, therefore, vNDV-PRV-
GB-gD vaccines have good protection.
Described above is only the preferred embodiments of the present invention, not does any formal limitation to the present invention, though
So the present invention is disclosed above with preferred embodiment, but is not limited to the present invention, any to be familiar with this professional technology people
Member, in the range of technical solution of the present invention is not departed from, when the technology contents using the disclosure above make a little change or repair
The equivalent embodiment for equivalent variations is adornd, as long as being the content without departing from technical solution of the present invention, the technology according to the present invention is real
Any simple modification, equivalent variations and modification that confrontation above example is made, still fall within the scope of technical solution of the present invention
It is interior.
Claims (4)
1. a kind of porcine pseudorabies virus vaccine combination, it is characterised in that described vaccine combination includes the gB of immune amount
Albumen, gD albumen and adjuvant；Wherein, described gB protein contents are that 25-50 μ g/ml, gD protein content are 25-50 μ g/ml；Institute
The gB proteins sequence stated is SEQ ID NO.3, and described gD proteins sequence is SEQ ID NO.4.
2. vaccine combination according to claim 1, it is characterised in that described gB protein contents are 25 μ g/ml, gD eggs
Bai Hanliang is 25 μ g/ml；Or described gB protein contents are that 50 μ g/ml, gD protein contents are 50 μ g/ml.
3. a kind of method for preparing any one of claim 1 vaccine combination, it is characterised in that described method includes：
1) the step of preparing gB albumen and gD proteantigens；And
2) hybrid antigen in proportion, adds the step of adjuvant, emulsification；Wherein, described gB protein contents are 25-50 μ g/ml；gD
Protein content is 25-50 μ g/ml.
4. the vaccine combination according to claim any one of 1-2 is preparing prevention and/or treatment porcine pseudorabies virus
Relevant disease or by the application in the medicine infected caused by porcine pseudorabies virus.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410519314.2A CN104248757B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and preparation method and application thereof |
| CN201510789015.5A CN105251000B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410519314.2A CN104248757B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and preparation method and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510789015.5A Division CN105251000B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104248757A CN104248757A (en) | 2014-12-31 |
| CN104248757B true CN104248757B (en) | 2017-10-27 |
Family
ID=52184231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510789015.5A Active CN105251000B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and its preparation method and application |
| CN201410519314.2A Active CN104248757B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510789015.5A Active CN105251000B (en) | 2014-09-30 | 2014-09-30 | Porcine pseudorabies virus vaccine composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105251000B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693827B (en) | 2015-06-29 | 2020-05-15 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus subunit vaccine and preparation method and application thereof |
| CN106267182B (en) * | 2015-06-29 | 2020-02-07 | 普莱柯生物工程股份有限公司 | Preparation method of porcine pseudorabies virus subunit vaccine, vaccine composition and application |
| CN106405082A (en) * | 2016-08-31 | 2017-02-15 | 洛阳普莱柯万泰生物技术有限公司 | Porcine pseudorabies virus detection test paper |
| CN107860921A (en) * | 2017-11-01 | 2018-03-30 | 杭州微瑞科技有限公司 | Pseudorabies virus antibody Quantitative detection card and application method |
| CN109134669B (en) * | 2018-09-19 | 2021-03-23 | 天康生物股份有限公司 | Fusion protein of porcine pseudorabies virus, preparation method, application and vaccine thereof |
| CN110066827B (en) * | 2019-04-29 | 2020-12-15 | 华中农业大学 | Recombinant baculovirus transfer vector containing porcine pseudorabies virus gB protein gene, recombinant baculovirus and preparation method and application |
| CN112011521A (en) * | 2020-06-15 | 2020-12-01 | 浙江迪福润丝生物科技有限公司 | Novel recombinant newcastle disease virus vector coronavirus vaccine candidate strain as well as construction method and application thereof |
| CN114146172B (en) * | 2021-12-07 | 2022-09-16 | 重庆市动物疫病预防控制中心 | Nano antibody vaccine capable of preventing porcine pseudorabies virus infection, preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1376200A (en) * | 1999-06-10 | 2002-10-23 | 梅瑞尔公司 | DNA vaccine-PCV |
| CN1705436A (en) * | 2002-10-15 | 2005-12-07 | 法国海布雷德斯公司 | Method for producing a mammal provided with resistance to an alpha-herpes virus mediated infection and mammal obtained by implementing said method and said mammal's progeny |
| CN101121023A (en) * | 1996-07-19 | 2008-02-13 | 梅瑞尔公司 | Polynucleotide vaccine formulations against porcine reproductive and respiratory diseases |
| CN102985112A (en) * | 2010-03-26 | 2013-03-20 | 国立大学法人东京大学 | Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| CN104004774A (en) * | 2013-05-31 | 2014-08-27 | 普莱柯生物工程股份有限公司 | Swine pseudorabies virus and vaccine composition as well as preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146642A (en) * | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| CA2678966A1 (en) * | 2007-02-21 | 2008-08-28 | Novavax, Inc. | Chimeric newcastle disease virus vlps |
| CN101376880B (en) * | 2008-09-24 | 2010-12-08 | 中国农业科学院哈尔滨兽医研究所 | Recombinant Newcastle Disease LaSota Attenuated Vaccine Strain Expressing Rabies Virus Glycoprotein (GP Protein) |
-
2014
- 2014-09-30 CN CN201510789015.5A patent/CN105251000B/en active Active
- 2014-09-30 CN CN201410519314.2A patent/CN104248757B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101121023A (en) * | 1996-07-19 | 2008-02-13 | 梅瑞尔公司 | Polynucleotide vaccine formulations against porcine reproductive and respiratory diseases |
| CN1376200A (en) * | 1999-06-10 | 2002-10-23 | 梅瑞尔公司 | DNA vaccine-PCV |
| CN1705436A (en) * | 2002-10-15 | 2005-12-07 | 法国海布雷德斯公司 | Method for producing a mammal provided with resistance to an alpha-herpes virus mediated infection and mammal obtained by implementing said method and said mammal's progeny |
| CN102985112A (en) * | 2010-03-26 | 2013-03-20 | 国立大学法人东京大学 | Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| CN104004774A (en) * | 2013-05-31 | 2014-08-27 | 普莱柯生物工程股份有限公司 | Swine pseudorabies virus and vaccine composition as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| A DNA vaccine coding for gB and gD of pseudorabies virus(suid herpes type 1) primes the immune system in the presence of maternal immunity more efficiently than conventional vaccines;E.M.A. van Rooij等;《Vaccine》;20051003;第24卷;摘要 * |
| 伪狂犬病亚单位疫苗研究进展;杨承槐等;《江西畜牧兽医杂志》;20041231(第3期);第5页左栏第5段至右栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104248757A (en) | 2014-12-31 |
| CN105251000A (en) | 2016-01-20 |
| CN105251000B (en) | 2018-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104248757B (en) | Porcine pseudorabies virus vaccine composition and preparation method and application thereof | |
| US9650424B2 (en) | Porcine pseudorabies virus, vaccine composition and preparation method and use thereof | |
| CN105567648B (en) | Recombination avian herpetoviruses carrier and vaccine for immunity inoculation aquatic bird species | |
| CN104250640A (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof | |
| CN105693827A (en) | Porcine pseudorabies virus subunit vaccine and preparation method and application thereof | |
| CN104988124A (en) | Genotype VII Newcastle disease virus marker vaccine strain and application thereof | |
| CN105018433B (en) | Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application | |
| CN105985966A (en) | Gene VII-type newcastle disease virus strain, vaccine composition thereof and preparing method and application of vaccine composition | |
| CN106267182A (en) | The preparation method of a kind of porcine pseudorabies virus subunit vaccine and vaccine combination and application | |
| CN108251382B (en) | Porcine pseudorabies virus weakening method, porcine pseudorabies virus weakening virus strain, porcine pseudorabies virus vaccine composition and application of porcine pseudorabies virus weakening virus strain | |
| CN106794242B (en) | Broad-spectrum vaccine against avian reovirus | |
| CN106031793A (en) | Active vaccine, and preparation method and application thereof | |
| CN106924726A (en) | A kind of vaccine combination for preventing porcine reproductive and respiratory syndrome and its preparation method and application | |
| CN107287168A (en) | A kind of NDV saves method and its application | |
| JP2015512396A (en) | Modified Marek's disease virus and vaccine produced from said virus | |
| CN104328090B (en) | A kind of porcine pseudorabies virus strain, vaccine composition and its preparation method and application | |
| CN105018436B (en) | Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application | |
| CN107326012A (en) | A kind of cell line and its application | |
| KR20210035675A (en) | Avian metapneumovirus vaccine with high tilter using Newcastle virus vector | |
| KR20210035676A (en) | Avian metapneumovirus vaccine with high tilter using Newcastle virus vector | |
| CN115261335B (en) | Oral immune avian influenza inactivated vaccine | |
| CN104248761A (en) | Vaccine composition, and preparation method and application thereof | |
| CN114099661B (en) | Application of replicative human type 3 adenovirus as expression vector in preparation of vaccine for pigs | |
| KR101560337B1 (en) | A novel Avian metapneumovirus and vaccine thereof | |
| Ismael et al. | Epidemiological Study on the Impact of Vaccination Programs on Antigenic Relatedness, Genetic Characterization of Highly pathogenic Avian Influenza H5N1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |